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Abstract
Background: Mutation in several podocyte-specific genes have been noted to result in phenotypic heterogeneity.
Herein, we report a novel, autosomal dominant TRPC6 mutation in a family with disease ranging from
asymptomatic minimal change disease to end-stage kidney disease.
Case presentation: A 35 year old woman developed asymptomatic, nephrotic range proteinuria during pregnancy
that did not resolve after delivery. Her mother had end-stage kidney disease of unknown etiology and her brother
had asymptomatic proteinuria. Kidney biopsy revealed minimal change disease in both the proband and her
brother. Genetic testing was performed in the proband and mother, revealing a novel frameshift mutation in TRPC6,
D873fsX878. The proband continues to have subnephrotic range proteinuria and normal creatinine but her brother
has since developed progressive chronic kidney disease.
Conclusions: The current case report underscores the heterogeneity of disease in podocytopathies and related
genes. Genetic testing of podocyte genes is useful in order to understand the pathophysiologic processes
underlying these overlapping diseases.
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Background
Diseases of the podocyte most commonly manifest as
minimal change disease (MCD) and focal segmental
glomerulosclerosis (FSGS) in children and adults,
respectively. A substantial proportion of both diseases
are due to genetic aberrations of genes that are important
to podocyte structure or function. The majority of the
currently recognized genetic forms of MCD and FSGS
follow simple Mendelian inheritance patterns [1].
Mutation in the podocyte-specific gene TRPC6 was
first identified as causing autosomal dominant (AD)
FSGS in 2005 [2,3]. A total of 16 mutations in TRPC6
have since been cited in both familial and sporadic FSGS
as well as in adult and childhood onset disease [2-11]. To
date, only a single family has been identified as having
kidney histopathology other than FSGS [8]. Herein, we
add to this body of literature by reporting a novel TRPC6
mutation in a family with phenotypic heterogeneity
ranging from asymptomatic minimal change disease to
end-stage kidney disease (ESKD).
Case presentation
A 34 year-old Korean woman was in her first trimester
of pregnancy when she developed proteinuria. She was
not edematous and did not have hypertension. Her
proteinuria became increasingly severe and by her third
trimester of pregnancy her urine protein to creatinine
ratio (UPC) was greater than 10 gm/gm. She was
induced at 37 weeks gestation and delivered a healthy
boy who had no complications. Her proteinuria did not
resolve following delivery and percutaneous kidney
biopsy was performed. This demonstrated 1 out of 20
globally sclerotic glomeruli with no other abnormalities
on light microscopy. Immunofluorescent staining was
negative. Electron microscopy revealed moderate podocyte
effacement and segmental basement membrane thinning.
She has persistently declined treatment, including use of
angiotensin converting enzyme inhibitors and all forms of
immunomodulatory therapy. Despite this, her UPC has
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been stable for several years at 1.0 gm/gm and her creatin-
ine has consistently measured less than 1.0 gm/dl.
There was suspicion of a genetic component to her dis-
ease as her mother had developed end-stage kidney disease
in her mid-50s and her brother had proteinuria progressing
to chronic kidney disease (Figure 1). The mother presented
with shrunken kidneys and had not been able to undergo
biopsy; she underwent kidney transplantation at 55 years
and has had no proteinuria since that time. The brother’s
clinical history has not been confirmed due to lack of con-
sent. Per his sister’s report, proteinuria was initially mild
and he opted against kidney biopsy until his proteinuria
worsened and he subsequently developed chronic renal in-
sufficiency. His biopsy reportedly demonstrated minimal
change disease and he was treated with oral steroids with-
out any improvement.
Genetic testing of TRPC6 was performed due to the
apparent autosomal dominant inheritance pattern.
She was found to be heterozygous for a novel TRPC6
frameshift mutation resulting from a 4 base pair GATA
deletion in exon 12 [c. 2617–2620 del GATA, p.
D873fsX878] (Figure 2). The reported mutation is novel,
as it has not been seen in over 90 patients with neph-
rotic syndrome sequenced in our laboratory, is not
reported in any dbSNP or exome sequencing databases
of normal controls, and has not been previously reported
in TRPC6. The resultant frameshift leads to a premature
stop codon, and is predicted to result in a truncated
TRPC6 protein lacking the C-terminal coiled coil
domain. The proband’s mother also tested positive for
the same mutation but her brother did not wish to be
tested. DNA sequencing for mutations in ACTN4, INF2,
and NPHS2 associated with adolescent or adult onset
nephrotic syndrome revealed no other mutations in this
family (data not shown). Due to segmental basement
membrane thinning on the proband’s kidney biopsy and
the possibility of X-linked transmission in this family, the
collagen 4 alpha 5 (COL4A5) gene was also sequenced in
the proband’s mother and was negative for mutations.
Figure 1 Genealogical tree of a non-consanguineous, Korean
family with minimal change disease and a novel TRPC6
deletion mutation in exon 12.
Figure 2 Sequence analysis of the novel TRPC6 mutation found in 3 family members. Shown is a partial electropherogram of Sanger DNA
sequencing analysis of TRPC6 exon12 from the proband. The arrow shows the position of the heterozygous four base pair deletion resulting in a
downstream frameshift. Shown above are the nucleotide and predicted amino acid sequences of the wild-type TRPC6 sequence (top line) and
the heterozygous four base pair deletion (bottom line). The deleted nucleotides (GATA) are depicted in red font. The four base pair deletion
results in a frame shift and premature protein truncation, five amino acids downstream [p.D873fsX878].
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Conclusions
TRPC6 is a transient receptor potential (TRP) channel
that plays a role in intracellular calcium signaling and is
expressed in a signaling complex with nephrin and podocin
in the podocyte slit diaphragm [1]. Although the reported
TRPC6 frameshift mutation is novel, it encodes a truncated
TRPC6 protein lacking the C-terminal coiled coil domain,
a highly conserved domain thought to play an essential
role in TRPC6 calcium channel function. This truncating
mutation is likely to have a dominant gain-of-function
effect similar to other known pathogenic TRPC6 mutations
(Table 1) [3,6]. Other TRPC6 mutations mapped to the
coiled-coil domain at the C-terminus, such as R895C and
E897K, have been demonstrated to result in increased
calcium ion influx [3,6]. The C-terminal K874X nonsense
mutation and N-terminal mutations within the ankyrin
repeats have demonstrated delayed calcium channel
inactivation, resulting in increased channel opening time
[5,12]. The D873fsX878 mutation results in protein
truncation only four amino acids downstream of the
truncating K874X mutation and may have a similar effect
on delaying calcium channel inactivation. The tracking of
this mutation with nephrotic syndrome in this family
supports an autosomal dominant gain of function effect.
The mechanism whereby increased calcium current leads
to the pathogenic manifestations of MCD or FSGS is
unknown. TRPC6 functions as a mechanoreceptor of
membrane stretch [1]. Other pathogenic mechanisms of
TRPC6 mutation that have been hypothesized include
altered channel regulation, altered interaction with other
slit diaphragm proteins, and altered protein turnover [3].
It has been speculated that mutations in TRPC6 may
result in apoptosis, podocyte detachment or an alteration
in the ultrafiltration coefficient [12,13].
To date, the vast majority of identified mutations in
TRPC6 have been associated with FSGS, including
collapsing glomerulopathy [2-8,10,11]. The current report
underscores the phenotypic heterogeneity that can occur
in podocyte-specific gene mutations. We have replicated
the finding that TRPC6 mutation can result in MCD as
Table 1 Mutations in TRPC6 protein currently identified to cause proteinuric kidney disease
TRPC6
mutation
Effect on ion channel function Level of evidence Ethnicity Phenotype Age at
presentation (years)
Reference
89fsX8 Not evaluated Caucasian FSGS 7 [7]
G109S Probably damaging In silico scoring matrix Caucasian FSGS 25 [6]
N125S Probably damaging In silico scoring matrix Caucasian sporadic FSGS 41 [6]
Increased intracellular calcium In Vitro experiments Caucasian MCD and IgAN with
MPGN-like pattern
4-14 [8]
M132T Increased current amplitude and
delayed channel inactivation
In Vitro experiments Caucasian AD FSGS 9-30 [5]
Not evaluated Caucasian FSGS 8 [7]
P112Q Increased current amplitude In Vitro experiments Caucasian AD FSGS 30-40 [2]
N143S None identified In Vitro experiments African American AD FSGS 30-40 [3]
None identified In Vitro experiments Caucasian AD FSGS 27-39 [5]
H218L Increased intracellular calcium In Vitro experiments Caucasian sporadic FSGS 8 [8]
S270T None identified In Vitro experiments Latino AD FSGS 20-50 [3]
R360H Not evaluated Not stated FSGS 34 [11]
L395A Not evaluated Caucasian sporadic FSGS 2 [10]
G757D Not evaluated Caucasian FSGS 1 [7]
L780P Possibly damaging In silico scoring matrix Caucasian sporadic FSGS 7 [6]
D873fsX878 Not evaluated MCD 34-50 Present study
K874X None identified In Vitro experiments Caucasian AD FSGS 30-60 [3]
Q889K Increased current amplitude In Vitro experiments Chinese AD FSGS >12 [4]
R895C Increased current amplitude In Vitro experiments Latino AD FSGS 20-50 [3]
Not evaluated Caucasian AD collapsing FSGS 21-38 [9]
R895L Increased intracellular calcium In Vitro experiments Caucasian sporadic collapsing
FSGS
1 [8]
E897K Increased current amplitude In Vitro experiments Caucasian AD FSGS 25-35 [3]
AD-Autosomal Dominant; FSGS-Focal Segmental Glomerulosclerosis; MCD-Minimal Change Disease; IgAN-IgA Nephropathy;
MPGN-Membranoproliferative Glomerulosclerosis.
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well as FSGS [8]. Gigante et al. (2011) previously reported
a family with a distinct TRPC6 mutation resulting in
childhood onset nephrotic syndrome, with one sibling
having MCD and another having IgAN with a mem-
branoproliferative-like pattern. In some cases, the finding
of MCD is due to unsampled FSGS and in other instances
it may represent an earlier clinical stage of FSGS, which
could be true in the present case. TRPC6 mutation has
traditionally been thought to cause familial, adult onset
disease; however, a significant number of sporadic
and childhood onset FSGS cases have been identified
[5-8]. Other podocyte-specific genes have also been
found to result in multiple pathologic and clinical disease
phenotypes. Mutations in podocin (NPHS2) have been
reported in FSGS, steroid resistant MCD and diffuse
mesangial sclerosis [14]. Phenotypic heterogeneity also
exists for nephrin (NPHS1) mutations which have been
reported to result in congenital nephrotic syndrome,
steroid-resistant MCD and FSGS [15]. Given the hetero-
geneity in disease that can result from mutations within
the same gene, it has been suggested that these disease
entities be referred to as ‘podocytopathies’ rather than by
their histologic phenotype [16].
This family demonstrates the significant heterogeneity
in clinical manifestations that can occur from the same
genetic mutation. Although genotype-phenotype correlation
of this novel TRPC6 mutation is not known, all three
affected adults presented with proteinuria at 32–34
years of age, with progressive chronic kidney disease
subsequently developing in the proband’s mother and
brother. However, the proband has thus far remained
stable following pregnancy-induced proteinuria without
any increase in creatinine. There are likely other genetic
and/or environmental modifiers that play a significant role
in disease penetrance and expressivity. Currently, there
are no known genetic modifiers of TRPC6-associated
disease. Modifiers for TRPC6-mediated podocytopathies
can be speculated when considering that TRPC6 is
partially regulated by podocin and is thought to be
assembled in a complex with nephrin. The R229Q
single nucleotide polymorphism in podocin (NPHS2)
results in decreased nephrin binding and can result in
both familial and seemingly sporadic FSGS when in a
compound heterozygous state with another deleterious
NPHS2 mutation [17]. Heterozygous lesions in collagen
IV have also been hypothesized to modify susceptibility to
FSGS [18]. Although sequence analysis of both NPHS2
and the X-linked collagen IV chain gene COL4A5 was
negative in this family, other genetic or environmental
factors may play a role in modifying disease severity
within a family and in determining whether TRPC6
mutation presents as FSGS or MCD in different families.
This case report underscores the complexity in nomen-
clature, pathogenesis and genetics of podocytopathies.
The clinical presentation, histological pattern, causative
genes and specific mutations should all be taken into
consideration when assessing a familial or even seemingly
sporadic case of proteinuria. Documentation of atypical
cases of familial proteinuric syndromes along with techno-
logical advances in genetic testing will facilitate a better
understanding of diseases of the podocyte.
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